ACACIA PHARMA GROUP LIMITED

• ⚠

  Material uncertainty over going concern

  The Directors considered the financial position of the Company and produced forecasts for the next 12 months from the date of signing these financial statements. These forecasts show that Company is reliant on the support of the entities comprising the group headed by its immediate and ultimate parent undertaking, Eagle Pharmaceuticals, Inc., in continuing as a going concern as it does not individually have the resources required to continue operations for a period of at least twelve months. Eagle Pharmaceuticals, Inc. currently has cash and cash equivalents on hand which its forecasts indicate will not be sufficient to continue to support the operations of the Company for at least 12 months from the date of signing the financial statements. While Eagle Pharmaceuticals, Inc is evaluating range of potential financing and other alternatives to strengthen its liquidity position, none of these alternatives were committed at the reporting date. The matters described above indicate the existence of a material uncertainty which may cast significant doubt on the Company's ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business.

1. ACACIA PHARMA GROUP LIMITED 2022-07-13 → present
2. ACACIA PHARMA GROUP PLC 2018-02-21 → 2022-07-13
3. ACACIA PHARMA GROUP LIMITED 2016-12-19 → 2018-02-21
4. ACACIA PHARMA GROUP PLC 2015-09-22 → 2016-12-19
5. ACACIA PHARMA GROUP LIMITED 2015-09-22 → 2015-09-22
6. CITYVIVA LIMITED 2015-09-02 → 2015-09-22

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

BDO LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“The Directors considered the financial position of the Company and produced forecasts for the next 12 months from the date of signing these financial statements. These forecasts show that Company is reliant on the support of the entities comprising the group headed by its immediate and ultimate parent undertaking, Eagle Pharmaceuticals, Inc., in continuing as a going concern as it does not individually have the resources required to continue operations for a period of at least twelve months. Eagle Pharmaceuticals, Inc. currently has cash and cash equivalents on hand which its forecasts indicate will not be sufficient to continue to support the operations of the Company for at least 12 months from the date of signing the financial statements. While Eagle Pharmaceuticals, Inc is evaluating range of potential financing and other alternatives to strengthen its liquidity position, none of these alternatives were committed at the reporting date. The matters described above indicate the existence of a material uncertainty which may cast significant doubt on the Company's ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business.”

Group structure

1. ACACIA PHARMA GROUP LIMITED · parent
   1. Acacia Pharma Limited 100% · Development and commercialization of pharmaceuticals
   2. Acacia Pharma, Inc. 100% · Indianapolis, IN · Sale and marketing of pharmaceuticals
   3. Acacia Pharma Ireland Limited 100% · Dublin 2 · Sale and marketing of pharmaceuticals

Significant events

• “On 28 February 2024, the Company's parent, Eagle Pharmaceuticals, Inc. approved and began implementing a plan designed to improve operational efficiencies and realign Eagle Pharmaceuticals, Inc.'s sales and marketing expenditures (the "Realignment Plan").”
• “The Realignment Plan reduced Eagle Pharmaceuticals, Inc.'s then current workforce by approximately 36%.”
• “On 1 October 2024, Eagle Pharmaceuticals, Inc. received a notice from the hearings panel of Nasdaq stating that it had determined to delist Eagle Pharmaceuticals, Inc.'s common stock from Nasdaq...”
• “On 27 November 2024, Eagle Pharmaceuticals, Inc. filed a Post-Effective Amendment with the Securities and Exchange Commission SEC to terminate the offerings of its securities pursuant to the Registration Statement.”
• “On March 31, 2025, Eagle Pharmaceuticals, Inc. used the net proceeds from the Blue Owl Agreement to repay, in full, all amounts outstanding under the credit agreement with its lender, JPMorgan Chase Bank, N.A. In connection with the repayment, the credit agreement was terminated and may no longer be utilized for borrowings.”
• “On January 24, 2025, Eagle Pharmaceuticals, Inc. informed Nasdaq of its intent to file Form 15 with the SEC to finalize the delisting of its common stock from the Nasdaq Global.”
• “In April 2025, Eagle Pharmaceuticals, Inc. determined certain net assets related to the Acacia business, including its BARHEMSYS® and BYFAVO products, met the criteria required to be classified as held-for-sale. Eagle Pharmaceuticals, Inc. is conducting a process for potential sale of the Acacia assets that is expected to be completed within the next 12 months; however, there is no assurance that the Acacia assets will be sold.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  —

  Not reported

• Net assets

  -3%

  -£3,171,000 → -£3,265,000

• Employees

  —

  Not reported

• Operating profit

  +99.9%

  -£95,816,000 → -£94,000

• Profit before tax

  +99.9%

  -£95,816,000 → -£94,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers